EVFM Stock Overview
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Evofem Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.026 |
52 Week High | US$4.38 |
52 Week Low | US$0.012 |
Beta | -1.2 |
1 Month Change | 23.22% |
3 Month Change | -62.32% |
1 Year Change | -99.05% |
3 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18Shareholder Returns
EVFM | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 64.6% | -0.2% | 0.6% |
1Y | -99.1% | 23.9% | 29.5% |
Return vs Industry: EVFM underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.
Return vs Market: EVFM underperformed the US Market which returned 29.5% over the past year.
Price Volatility
EVFM volatility | |
---|---|
EVFM Average Weekly Movement | 36.4% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EVFM's share price has been volatile over the past 3 months.
Volatility Over Time: EVFM's weekly volatility has increased from 27% to 36% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 36 | Saundra Pelletier | https://www.evofem.com |
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis.
Evofem Biosciences, Inc. Fundamentals Summary
EVFM fundamental statistics | |
---|---|
Market cap | US$1.22m |
Earnings (TTM) | US$55.96m |
Revenue (TTM) | US$18.22m |
0.0x
P/E Ratio0.1x
P/S RatioIs EVFM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EVFM income statement (TTM) | |
---|---|
Revenue | US$18.22m |
Cost of Revenue | US$6.51m |
Gross Profit | US$11.71m |
Other Expenses | -US$44.26m |
Earnings | US$55.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.19 |
Gross Margin | 64.26% |
Net Profit Margin | 307.19% |
Debt/Equity Ratio | -69.9% |
How did EVFM perform over the long term?
See historical performance and comparison